A retrospective analysis at Hospital 12 de Octubre shows excellent outcomes in intermediate-risk PAM50 patients, yet relapses that call for refining risk stratification....
An analysis of the Spanish El Álamo IV registry shows that age, stage, histological grade and tumour subtype are linked to distinct relapse patterns....
The Spanish SOLTI-1303 PATRICIA trial shows the triplet improves progression-free survival versus standard care in HER2-positive luminal tumours....
The Spanish SOLTI-1716 TATEN trial sees favourable responses and survival when combining pembrolizumab and paclitaxel in HER2-enriched or basal-like tumours....
An ESTRO expert panel reviews 27 phase I and phase II studies on radiotherapy before surgery in breast cancer and sets out its future perspectives....
A phase IIa trial evaluates ceralasertib, an oral ATR inhibitor, in advanced tumours with ATM alterations. Objective responses were limited, although the safety profile was manageable....
A Spanish pilot study reports five-year results of a hypofractionated chemoradiotherapy strategy before surgery in HER2-positive and triple-negative breast cancer....
A genomic analysis of the NeoTRIPaPDL1 trial identifies tumour features and early changes during treatment associated with response to neoadjuvant chemoimmunotherapy....
An updated review covers the evidence on the HER2DX genomic test to individualise treatment intensity in early-stage HER2-positive breast cancer....
The PERUSE study confirms in 1,436 patients with advanced HER2-positive breast cancer a median overall survival of more than five years with pertuzumab and trastuzumab plus a taxane....
A phase I/II trial evaluates the first conditionally activated antibody-drug conjugate against CD166, with clinical and translational activity across several tumour types, including breast cancer....
A translational analysis of the GEICAM PEARL trial shows that blood thymidine kinase is a prognostic marker and that its early changes provide treatment-specific information....